CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

Post-LOE

clotrimazole and betamethasone dipropionate

PharmaIN

ANDATOPICALLOTION

Approved

Jul 2004

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE (clotrimazole and betamethasone dipropionate) by PharmaIN is mechanism of action clotrimazole is an imidazole antifungal agent. Approved for older for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, tinea corporis due to epidermophyton floccosum and 2 more indications. First approved in 2004.

Drug data last refreshed 22h ago

Mechanism of Action

Mechanism of Action Clotrimazole is an imidazole antifungal agent. Imidazoles inhibit 14-α-demethylation of lanosterol in fungi by binding to one of the cytochrome P-450 enzymes. This leads to the accumulation of 14-α-methylsterols and reduced concentrations of ergosterol, a sterol essential for a…

Pharmacologic Class:

Azole Antifungal

Indications (5)

older for the topical treatment of symptomatic inflammatory tinea pedis tinea cruris

Worked on CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.